Hongli Yin

Hongli Yin

Auto-generated profile, based on publicly available information

Hongli Yin

Department of Endocrinology Endocrine and Metabolic Disease Medical Center Nanjing Drum Tower Hospital Affiliated Hospital of Medical School Nanjing University Nanjing 210008 China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2019 in PeerJ
Verified
Journal Article
Open access
PDF file
HYHongli Yin
Hongli Yin
JMJi Ma
Ji Ma
JHJichun Han
Jichun Han
MLMaoru Li
Maoru Li
JSJing Shang
Jing Shang
Background: Quercetin (Qr), isoquercitrin (IQ), and quercetin-3-O-β-D-glucuronide (QG) are powerful phytochemicals that have been shown to exhibit disease prevention and health promotion properties. However, there may exist transformations between Qr, IQ, and QG in vivo. And the pharmacokinetic profiles of Qr, IQ, and QG have not been systematically compared. The pharmacokinetics study would be helpful to better understand the pharmacological actions of them. Methods: Herein, we developed a reliable HPLC-MS method to compare the pharmacokinetics of Qr, IQ, and QG after separate (50 mg/kg) oral administration of them in rats, using puerarin as internal standard. The detection was performed using negative selected ion monitoring. This method was validated in terms of selectivity, linearity, precision, accuracy, extraction recovery, matrix effect, and stability; and shows reliabilities in monitoring the pharmacokinetic behaviors of these three compounds. Results: Our results showed that after separate oral administration of Qr, IQ, and QG, all of the compounds could be detected in plasma. In addition, QG could be detected in the Qr group; Qr and QG could be measured in the IQ group; and Qr could be found in rat plasma after 1.5 h of QG administration. Moreover, the AUC0−t of Qr in the; Qr group (2,590.5 ± 987.9 mg/L*min), IQ group (2,212.7 ± 914.1 mg/L*min), and QG group (3,505.7 ± 1,565.0 mg/L*min) was larger than the AUC0−t of QG in the; Qr group (1,550.0 ± 454.2 mg/L*min), IQ group (669.3 ± 188.3 mg/L*min), and QG group (962.7 ± 602.3 mg/L*min). The AUC0−t of IQ was the lowest among all groups. Discussion: Quercetin, IQ, and QG can all be absorbed into plasma. A mutual transformation exists between Qr and QG, and IQ can be metabolized into Qr and QG in SD rats. These results would provide a meaningful basis for understanding the pharmacological actions of these three compounds.

30 June 2025 in Advanced Science
Verified
Journal Article
Open access
HYHongli Yin
Hongli Yin
WTWenjuan Tang
Wenjuan Tang
DHDanqing Huang
Danqing Huang
JGJingJing Gan
JingJing Gan
PZPengzi Zhang
Pengzi Zhang
YBYan Bi
Yan Bi
Hormonal mechanisms of fatty liver formation require in‐depth exploration, and corresponding therapeutic strategies are urgently needed. Here, through serological testing of mice with fatty liver, it is found that the rhythms of prolactin secretion are disturbed and that the circulating prolactin level is reduced. Based on these findings, prolactin's biological effects on fatty liver are investigated, and biomimetic photothermal‐responsive core–shell microneedles with periodically prolactin releasing are proposed to inhibit lipid accumulation in liver. The microneedles are comprised of poly(lactic‐ co ‐glycolic acid) shells and prolactin‐loaded cores of photothermal black phosphorus, phase‐change gelatin, and carrageenan. Under periodically stimulation of near infrared (NIR), the prolactin in the microneedles can be released in a rhythmic manner for inhibiting the lipid accumulation in liver cells. Based on these features, it is demonstrated in mice with fatty liver that the bioinspired‐responsive microneedles can facilitate prolactin mitigating hepatic steatosis through its interaction with the hepatic prolactin receptor (PRLR) and by modulating the expression of fatty acid translocase (FAT/CD36). Thus, these photothermal‐responsive core–shell microneedles with prolactin pulse release hold significant promise for the treatment of fatty liver disease.